PMV Pharmaceuticals Posts $0 Revenue, $(1.48) EPS in FY2025 10-K
summarizeSummary
PMV Pharmaceuticals filed its 10-K for fiscal year 2025, reporting $0 revenue and a net loss of $77.7 million, or $(1.48) per share. This annual financial disclosure follows yesterday's news of OrbiMed Advisors fully exiting their position in the company, which places additional scrutiny on PMVP's financial health. The significant net loss and zero revenue highlight the company's pre-commercial stage and high burn rate, which is material for a company with an $81 million market cap. Management expects its cash and securities to fund operations into Q2 2027. Investors will monitor the progress of its lead candidate, rezatapopt, in the pivotal Phase 2 PYNNACLE trial and the planned NDA submission in Q1 2027, as these milestones are critical for future revenue generation.
At the time of this announcement, PMVP was trading at $1.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81.4M. The 52-week trading range was $0.81 to $1.88. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.